---
title: "GENFIT reports positive safety and anti-inflammatory activity of ACLF lead drug G1090N in Phase 1 trial."
description: "On January 6, 2026, in Lille, Cambridge, and Zurich, GENFIT (Euronext: GNFT), a biopharmaceutical company, revealed promising results for their lead investigational drug candidate, G1090N, targeted at"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271682978.md"
published_at: "2026-01-06T17:14:08.000Z"
---

# GENFIT reports positive safety and anti-inflammatory activity of ACLF lead drug G1090N in Phase 1 trial.

> On January 6, 2026, in Lille, Cambridge, and Zurich, GENFIT (Euronext: GNFT), a biopharmaceutical company, revealed promising results for their lead investigational drug candidate, G1090N, targeted at treating Acute-On-Chronic Liver Failure (ACLF). The drug, a small molecule, displayed positive Phase 1 safety outcomes and exhibited potent anti-inflammatory properties in ex-vivo research. GENFIT focuses on assisting patients with rare and severe liver disorders.

On January 6, 2026, in Lille, Cambridge, and Zurich, GENFIT (Euronext: GNFT), a biopharmaceutical company, revealed promising results for their lead investigational drug candidate, G1090N, targeted at treating Acute-On-Chronic Liver Failure (ACLF). The drug, a small molecule, displayed positive Phase 1 safety outcomes and exhibited potent anti-inflammatory properties in ex-vivo research. GENFIT focuses on assisting patients with rare and severe liver disorders.

### Related Stocks

- [GNFTY.US - GENFIT SPON ADS EACH REP 1 ORD SHS](https://longbridge.com/en/quote/GNFTY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Genfit SA 在最新的公司報告中突出了其研發管線的進展以及商業上的成功 | Genfit SA 更新了其商業、臨牀和研究活動，報告了 Iqirvo® 在原發性膽汁性膽管炎方面的強勁銷售。該公司正在推進其研究候選藥物 G1090N 用於急性加重慢性肝衰竭的二期研究，並預計在 2026 年進行其腫瘤學項目 GNS561 | [Link](https://longbridge.com/en/news/275149217.md) |
| Genfit SA 發佈 2025 財年股東信 | Genfit SA 發佈了其 2026 年 2 月的第 19 封股東信。完整信件可以通過提供的鏈接訪問。此新聞簡報由公共技術公司（PUBT）使用人工智能生成，僅供信息參考，不構成財務、投資或法律建議。Genfit SA 對 2026 年 2 | [Link](https://longbridge.com/en/news/275346870.md) |
| 美國最危險的工作揭曉 | 在 2024 年，美國記錄了 5,070 起致命工作傷害，比 2023 年減少了 4%。卡車司機和建築工人受到的影響尤為明顯，卡車司機的死亡人數達到了 798 人。道路事故減少了 8.5%，而行人事故則上升了 19%。謀殺和自殺導致 733 | [Link](https://longbridge.com/en/news/276462715.md) |
| IDT 澳大利亞公司報告稱，通過新的領導團隊和重組戰略，其運營得到了改善 | IDT 澳大利亞在新的領導團隊和重新調整戰略下報告了運營改善，截止 12 月 31 日的六個月內，普通收入增長 20.3%，達到 840 萬美元。EBITDA 改善為虧損 43.6 萬美元，正常化的中期 EBITDA 為負 25.6 萬美元 | [Link](https://longbridge.com/en/news/276194130.md) |
| FDA 負責人警告美國在早期藥物開發上正在被中國趕超，呼籲加快試驗審批速度 | FDA 專員 Marty Makary 警告稱，美國在早期藥物開發方面正失去對中國的競爭優勢。他指出了三個主要瓶頸：醫院合同、倫理審查以及他所描述的低效的臨牀試驗新藥申請流程。Makary 強調需要進行改革，以簡化試驗審批，並建議與醫療系統 | [Link](https://longbridge.com/en/news/276268124.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.